Management of children with multiple sclerosis

Pediatric Drugs

Volumn 14, Issue 3, 2012, Pages 165-177

  Yeh, E Ann ^a,b  

^a UNIVERSITY OF TORONTO   (Canada)

^b HOSPITAL FOR SICK CHILDREN   (Canada)

Author keywords

Children; Cyclophosphamide; Mitoxantrone; Multiple sclerosis; Natalizumab

Indexed keywords

BACLOFEN; BOTULINUM TOXIN; CYCLOPHOSPHAMIDE; DIAZEPAM; GLATIRAMER; INTERFERON; MITOXANTRONE; MODAFINIL; NATALIZUMAB;

AFFECTIVE PSYCHOSIS; ARTICLE; CEREBRAL PALSY; CHILDHOOD DISEASE; COGNITIVE DEFECT; EXERCISE; FATIGUE; FOLLOW UP; HEMATOLOGIC MALIGNANCY; HUMAN; MULTIPLE SCLEROSIS; OPPORTUNISTIC INFECTION; PRIORITY JOURNAL; PROGRESSIVE MULTIFOCAL LEUKOENCEPHALOPATHY; PSYCHIATRIC TREATMENT; PSYCHOSOCIAL DISORDER; SPASTICITY;

AGE OF ONSET; ANTIBODIES, MONOCLONAL, HUMANIZED; CHILD; CYCLOPHOSPHAMIDE; FATIGUE; HUMANS; IMMUNOLOGIC FACTORS; IMMUNOSUPPRESSIVE AGENTS; INTERFERONS; MITOXANTRONE; MULTIPLE SCLEROSIS; MUSCLE SPASTICITY; PEPTIDES;

EID: 84859804793     PISSN: 11745878     EISSN: 11792019     Source Type: Journal    
DOI: 10.2165/11596330-000000000-00000     Document Type: Article

References (138)

1. Yeh EA, Weinstock-Guttman B, Ramanathan M, et al. Magnetic resonance imaging characteristics of children and adults with paediatric-onset multiple sclerosis. Brain 2009 Dec; 132 (Pt 12): 3392-400
2. Amato MP, Goretti B, Ghezzi A, et al. Cognitive and psychosocial features in childhood and juvenile MS: two-year follow-up. Neurology 2010 Sep 28; 75 (13): 1134-40
3. Amato MP, Goretti B, Ghezzi A, et al. Cognitive and psychosocial features of childhood and juvenile MS. Neurology 2008 May 13; 70 (20): 1891-7 (Pubitemid 351684642)
4. Banwell B, Kennedy J, Sadovnick D, et al. Incidence of acquired demyelination of the CNS in Canadian children. Neurology 2009 Jan 20; 72 (3): 232-9
5. Mikaeloff Y, Suissa S, Vallee L, et al. First episode of acute CNS inflammatory demyelination in childhood: prognostic factors for multiple sclerosis and disability. J Pediatr 2004 Feb; 144 (2): 246-52 (Pubitemid 38869403)
6. Krupp LB, Banwell B, Tenembaum S. Consensus definitions proposed for pediatric multiple sclerosis and related disorders. Neurology 2007 Apr 17; 68 (16 Suppl. 2): S7-12 (Pubitemid 46626001)
7. Polman CH, Reingold SC, Banwell B, et al. Diagnostic criteria for multiple sclerosis: 2010 revisions to the McDonald criteria. Ann Neurol 2011; 69 (2): 292-302
8. Barkhof F, Filippi M, Miller DH, et al. Comparison of MRI criteria at first presentation to predict conversion to clinically definite multiple sclerosis. Brain 1997 Nov; 120 (Pt 11): 2059-69 (Pubitemid 27493740)
9. McDonald WI, Compston A, Edan G, et al. Recommended diagnostic criteria for multiple sclerosis: guidelines from the International Panel on the diagnosis of multiple sclerosis. Ann Neurol 2001 Jul; 50 (1): 121-7
10. Hahn CD, Shroff MM, Blaser SI, et al. MRI criteria for multiple sclerosis: evaluation in a pediatric cohort. Neurology 2004 Mar 9; 62 (5): 806-8 (Pubitemid 38298964)
11. Callen DJ, Shroff MM, Branson HM, et al. MRI in the diagnosis of pediatric multiple sclerosis. Neurology 2009 Mar 17; 72 (11): 961-7
12. Callen DJ, Shroff MM, Branson HM, et al. Role of MRI in the differentiation of ADEM from MS in children. Neurology 2009 Mar 17; 72 (11): 968-73
13. Ketelslegers IA, Neuteboom RF, Boon M, et al. A comparison of MRI criteria for diagnosing pediatric ADEM and MS. Neurology 2010 May 4; 74 (18): 1412-5
14. Banwell B, Tenembaum S, Lennon VA, et al. Neuromyelitis oPtica-IgG in childhood inflammatory demyelinating CNS disorders. Neurology 2008 Jan 29; 70 (5): 344-52 (Pubitemid 351653396)
15. Verhey LH, Branson HM, Makhija M, et al. Magnetic resonance imaging features of the spinal cord in pediatric multiple sclerosis: a preliminary study. Neuroradiology 2010 Dec; 52 (12): 1153-62
16. Lim BC, Hwang H, Kim KJ, et al. Relapsing demyelinating CNS disease in a Korean pediatric population: multiple sclerosis versus neuromyelitis oPtica. Mult Scler 2011 Jan; 17 (1): 67-73
17. Huppke P, Bluthner M, Bauer O, et al. Neuromyelitis oPtica and NMO-IgG in European pediatric patients. Neurology 2010 Nov 9; 75 (19): 1740-4
18. Waubant E, Chabas D, Okuda DT, et al. Difference in disease burden and activity in pediatric patients on brain magnetic resonance imaging at time of multiple sclerosis onset vs adults. Arch Neurol 2009 Aug; 66 (8): 967-71
19. Mesaros S, Rocca MA, Absinta M, et al. Evidence of thalamic gray matter loss in pediatric multiple sclerosis. Neurology 2008 Mar 25; 70 (13 Pt 2): 1107-12 (Pubitemid 351464767)
20. Gorman MP, Healy BC, Polgar-Turcsanyi M, et al. Increased relapse rate in pediatric-onset compared with adult-onset multiple sclerosis. Arch Neurol 2009 Jan; 66 (1): 54-9
21. Simone IL, Carrara D, TortorellaC, et al. Course and prognosis in early-onset MS: comparison with adult-onset forms. Neurology 2002 Dec 24; 59 (12): 1922-8 (Pubitemid 36076565)
22. Renoux C, Vukusic S, Mikaeloff Y, et al. Natural history of multiple sclerosis with childhood onset. N Engl J Med 2007 Jun 21; 356 (25): 2603-13 (Pubitemid 46961005)
23. Banwell BL, Anderson PE. The cognitive burden of multiple sclerosis in children. Neurology 2005 Mar 8; 64 (5): 891-4 (Pubitemid 40316333)
24. MacAllister WS, Belman AL, Milazzo M, et al. Cognitive functioning in children and adolescents with multiple sclerosis. Neurology 2005 Apr 26;64 (8): 1422-5 (Pubitemid 40570512)
25. Smerbeck A, Parrish J, Serafin D, et al. Visual-cognitive processing deficits in pediatric multiple sclerosis. Mult Scler 2011 Apr; 17 (4): 449-56
26. Mikaeloff Y, Caridade G, Tardieu M, et al. Effectiveness of early beta interferon on the first attack after confirmed multiple sclerosis: a comparative cohort study. Eur J Paediatr Neurol 2008 May; 12 (3): 205-9 (Pubitemid 351545847)
27. Fischer JS, Priore RL, Jacobs LD, et al. Neuropsychological effects of interferon beta-1a in relapsing multiple sclerosis. Multiple Sclerosis Collaborative Research Group. Ann Neurol 2000 Dec; 48 (6): 885-92
28. Barak Y, Achiron A. Effect of interferon-beta-1b on cognitive functions in multiple sclerosis. Eur Neurol 2002; 47 (1): 11-4
29. Kappos L, Freedman MS, Polman CH, et al. Long-term effect of early treatment with interferon beta-1b after a first clinical event suggestive of multiple sclerosis: 5-year active treatment extension of the phase 3 BENEFIT trial. Lancet Neurol 2009 Nov; 8 (11): 987-97
30. Weinstein A, Schwid SR, Schiffer RB, et al. Neuropsychologic status in multiple sclerosis after treatment with glatiramer. Arch Neurol 1999 Mar;56 (3): 319-24 (Pubitemid 29120229)
31. Brusaferri F, Candelise L. Steroids for multiple sclerosis and oPtic neuritis: a meta-analysis of randomized controlled clinical trials. J Neurol 2000 Jun; 247 (6): 435-42 (Pubitemid 30433557)
32. Beck RW. The oPtic neuritis treatment trial: three-year follow-up results. Arch Ophthalmol 1995 Feb; 113 (2): 136-7
33. Waldman AT, Gorman MP, Rensel MR, et al. Management of pediatric central nervous system demyelinating disorders: consensus of United States neurologists. J Child Neurol 2011 Jun; 26 (6): 675-82
34. Visser LH, Beekman R, Tijssen CC, et al. A randomized, double-blind, placebo-controlled pilot study of i.v. immune globulins in combination with i.v. methylprednisolone in the treatment of relapses in patients with MS. Mult Scler 2004 Feb; 10 (1): 89-91 (Pubitemid 38100534)
35. Sorensen PS, Haas J, Sellebjerg F, et al. IV immunoglobulins as add-on treatment to methylprednisolone for acute relapses in MS. Neurology 2004 Dec 14; 63 (11): 2028-33 (Pubitemid 39636247)
36. Straussberg R, Schonfeld T, Weitz R, et al. Improvement of atypical acute disseminated encephalomyelitis with steroids and intravenous immunoglobulins. Pediatr Neurol 2001 Feb; 24 (2): 139-43 (Pubitemid 32280298)
37. Spalice A, Properzi E, Lo Faro V, et al. Intravenous immunoglobulin and interferon: successful treatment of oPtic neuritis in pediatric multiple sclerosis. J Child Neurol 2004 Aug; 19 (8): 623-6
38. Shahar E, Andraus J, Savitzki D, et al. Outcome of severe encephalomyelitis in children: effect of high-dose methylprednisolone and immunoglobulins. J Child Neurol 2002 Nov; 17 (11): 810-4 (Pubitemid 36193070)
39. Rodriguez M, Karnes WE, Bartleson JD, et al. Plasmapheresis in acute episodes of fulminant CNS inflammatory demyelination. Neurology 1993 Jun; 43 (6): 1100-4 (Pubitemid 23177705)
40. Llufriu S, Castillo J, Blanco Y, et al. Plasma exchange for acute attacks of CNS demyelination: predictors of improvement at 6 months. Neurology 2009 Sep 22; 73 (12): 949-53
41. Schilling S, Linker RA, Konig FB, et al. Plasma exchange therapy for steroidunresponsive multiple sclerosis relapses: clinical experience with 16 patients. Nervenarzt 2006 Apr; 77 (4): 430-8
42. Takahashi I, Sawaishi Y, TakedaO, et al. Childhood multiple sclerosis treated with plasmapheresis. Pediatr Neurol 1997 Jul; 17 (1): 83-7 (Pubitemid 27387928)
43. Hauser SL, Waubant E, Arnold DL, et al. B-cell depletion with rituximab in relapsing-remittingmultiple sclerosis.NEngl JMed 2008 Feb 14; 358 (7): 676-88 (Pubitemid 351240747)
44. Bar-Or A, Calabresi PA, Arnold D, et al. Rituximab in relapsing-remitting multiple sclerosis: a 72-week, open-label, phase I trial. Ann Neurol 2008 Mar; 63 (3): 395-400 (Pubitemid 351499869)
45. Bielekova B, Richert N, Howard T, et al. Humanized anti-CD25 (daclizumab) inhibits disease activity in multiple sclerosis patients failing to respond to interferon beta. Proc Natl Acad Sci U S A 2004 Jun 8; 101 (23): 8705-8 (Pubitemid 38745835)
46. Krishnan C, Kaplin AI, Brodsky RA, et al. Reduction of disease activity and disability with high-dose cyclophosphamide in patients with aggressive multiple sclerosis. Arch Neurol 2008 Aug; 65 (8): 1044-51
47. Then Bergh F, Kumpfel T, Schumann E, et al. Monthly intravenous methylprednisolone in relapsing-remitting multiple sclerosis-reduction of enhancing lesions, T2 lesion volume and plasma prolactin concentrations. BMC Neurol 2006; 6: 19
48. Fazekas F, Deisenhammer F, Strasser-Fuchs S, et al. Randomised placebocontrolled trial of monthly intravenous immunoglobulin therapy in relapsingremitting multiple sclerosis. Austrian Immunoglobulin in Multiple Sclerosis Study Group. Lancet 1997 Mar 1; 349 (9052): 589-93 (Pubitemid 27101884)
49. Cohen JA, Barkhof F, Comi G, et al. Oral fingolimod or intramuscular interferon for relapsing multiple sclerosis. N Engl J Med 2010 Feb 4; 362 (5): 402-15
50. Giovannoni G, Comi G, Cook S, et al. A placebo-controlled trial of oral cladribine for relapsing multiple sclerosis. N Engl J Med 2010 Feb 4; 362 (5): 416-26
51. Kappos L, Radue EW, OConnor P, et al. A placebo-controlled trial of oral fingolimod in relapsing multiple sclerosis. N Engl J Med 2010 Feb 4; 362 (5): 387-401
52. Group IMSS. Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. I Clinical results of a multicenter, randomized, double blind, placebo- controlled trial. Neurology 1993; 655-61
53. Jacobs L, Cookfair D, Rudick R, et al. Intramuscular interferon beta-1a for disease progression in relapsing multiple sclerosis. Ann Neurol 1996; 39: 285-94 (Pubitemid 26100751)
54. Group PPoRaDbIb-asiMSS. Randomized double-blind placebo-controlled study of interferon b-1a in relapsing/remitting multiple sclerosis. Lancet 1998; 352: 1498-504
55. Ghezzi A, Amato MP, Capobianco M, et al. Treatment of early-onset multiple sclerosis with intramuscular interferonbeta-1a: long-term results. Neurol Sci 2007 Jun; 28 (3): 127-32 (Pubitemid 47039838)
56. Mikaeloff Y, Moreau T, Debouverie M, et al. Interferon-beta treatment in patients with childhood-onset multiple sclerosis. J Pediatr 2001 Sep; 139 (3): 443-6 (Pubitemid 32889524)
57. Banwell B, Reder AT, Krupp L, et al. Safety and tolerability of interferon beta-1b in pediatric multiple sclerosis. Neurology 2006 Feb 28; 66 (4): 472-6 (Pubitemid 43739870)
58. Bykova OV, Kuzenkova LM, Maslova OI. The use of beta-interferon-1b in children and adolescents with multiple sclerosis. Zh Nevrol Psikhiatr Im S Korsakova 2006; 106 (9): 29-33
59. Pohl D, Rostasy K, Gartner J, et al. Treatment of early onset multiple sclerosis with subcutaneous interferon beta-1a. Neurology 2005 Mar 8; 64 (5): 888-90 (Pubitemid 40316332)
60. Waubant E, Hietpas J, Stewart T, et al. Interferon beta-1a in children with multiple sclerosis is well tolerated. Neuropediatrics 2001 Aug; 32 (4): 211-3 (Pubitemid 32895904)
61. Yeh E, Waubant E, Krupp L, et al. Multiple sclerosis therapies in pediatric patients with refractory multiple sclerosis. Arch Neurol 20011 Apr; 68 (4): 437-44
62. Tenembaum SN, Segura MJ. Interferon beta-1a treatment in childhood and juvenile-onset multiple sclerosis. Neurology 2006 Aug 8; 67 (3): 511-3 (Pubitemid 44214986)
63. Malucchi S, Sala A, Gilli F, et al. Neutralizing antibodies reduce the efficacy of betaIFN during treatment of multiple sclerosis. Neurology 2004 Jun 8; 62 (11): 2031-7 (Pubitemid 38738217)
64. Perini P, Calabrese M, Biasi G, et al. The clinical impact of interferon beta antibodies in relapsing-remitting MS. J Neurol 2004 Mar; 251 (3): 305-9 (Pubitemid 38387148)
65. Bertolotto A, Gilli F, Sala A, et al. Persistent neutralizing antibodies abolish the interferon beta bioavailability inMSpatients. Neurology 2003 Feb 25; 60 (4): 634-9 (Pubitemid 36246082)
66. Rudick RA, Simonian NA, Alam JA, et al. Incidence and significance of neutralizing antibodies to interferon beta-1a in multiple sclerosis. Multiple Sclerosis Collaborative Research Group (MSCRG). Neurology 1998 May; 50 (5): 1266-72 (Pubitemid 28240338)
67. Neutralizing antibodies during treatment of multiple sclerosis with interferon beta-1b: experience during the first three years. The IFNB Multiple Sclerosis Study Group and the University of British Columbia MS/MRI Analysis Group. Neurology 1996 Oct; 47 (4): 889-94
68. Yeh E, Heim R, Karpinski M, et al. Neutralizing antibodies to interferon in children with MS on interferon treatment. Toronto (ON): American Academy of Neurology, 2010
69. Dhib-Jalbut S. Sustained immunological effects of Glatiramer acetate in patients with multiple sclerosis treated for over 6 years. J Neurol Sci 2002; 201: 71-7 (Pubitemid 34876908)
70. Johnson KP, Brooks BR, Cohen JA, et al. Copolymer 1 reduces relapse rate and improves disability in relapsing-remitting multiple sclerosis: results of a phase III multicenter, double-blind placebo-controlled trial. The Copolymer 1 Multiple Sclerosis Study Group. Neurology 1995 Jul; 45 (7): 1268-76
71. Comi G, Filippi M, Wolinsky JS. European/Canadian multicenter, doubleblind, randomized, placebo-controlled study of the effects of glatiramer acetate on magnetic resonance imaging-measured disease activity and burden in patients with relapsing multiple sclerosis. European/Canadian Glatiramer Acetate Study Group. Ann Neurol 2001 Mar; 49 (3): 290-7 (Pubitemid 32202781)
72. Cadavid D, Wolansky LJ, Skurnick J, et al. Efficacy of treatment of MS with IFNbeta-1b or glatiramer acetate by monthly brain MRI in the BECOME study. Neurology 2009 Jun 9; 72 (23): 1976-83
73. Ghezzi A. Immunomodulatory treatment of early onset multiple sclerosis: results of an Italian Co-operative Study. Neurol Sci 2005 Dec; 26 Suppl. 4: S183-6 (Pubitemid 43085208)
74. Ghezzi A, Amato MP, Capobianco M, et al. Disease-modifying drugs in childhood-juvenile multiple sclerosis: results of an Italian co-operative study. Mult Scler 2005 Aug; 11 (4): 420-4 (Pubitemid 40984236)
75. Kornek B, Bernert G, Balassy C, et al. Glatiramer acetate treatment in patients with childhood and juvenile onset multiple sclerosis. Neuropediatrics 2003 Jun; 34 (3): 120-6 (Pubitemid 36994400)
76. Thannhauser JE, Mah JK, Metz LM. Adherence of adolescents to multiple sclerosis disease-modifying therapy. Pediatr Neurol 2009 Aug; 41 (2): 119-23
77. Chitnis T, Tenembaum S, Banwell B, et al. Consensus statement: evaluation of new and existing therapeutics for pediatric multiple sclerosis. Mult Scler 2012 Jan; 18 (1): 116-27
78. Rudick RA, Stuart WH, Calabresi PA, et al. Natalizumab plus interferon beta-1a for relapsing multiple sclerosis. N Engl J Med 2006 Mar 2; 354 (9): 911-23
79. Polman CH, OConnor PW, Havrdova E, et al. A randomized, placebocontrolled trial of natalizumab for relapsing multiple sclerosis.NEngl J Med 2006 Mar 2; 354 (9): 899-910
80. VanAssche G, Ranst MV, Sciot R, et al. Progressive multifocal leukoencephalopathy after natalizumab therapy for Crohns disease. N Engl J Med 2005; 353: 362-8 (Pubitemid 41132340)
81. Langer-Gould A, Atlas S, Green A, et al. Progressive multifocal encephalopathy in a patient treated with natalizumab. N Engl J Med 2005; 353: 375-81 (Pubitemid 41132342)
82. Kleinschmidt-DeMasters B, Tyler K. Progressive multifocal leukoencephalopathy complicating treatment with natalizumab and interferon beta-1a for multiple sclerosis. N Engl J Med 2005; 353: 369-74 (Pubitemid 41132341)
83. Yousry TA, Major EO, Ryschkewitsch C, et al. Evaluation of patients treated with natalizumab for progressive multifocal leukoencephalopathy. N Engl J Med 2006 Mar 2; 354 (9): 924-33
84. Knowles WA, Pipkin P, Andrews N, et al. Population-based study of antibody to the human polyomaviruses BKV and JCV and the simian polyomavirus SV40. J Med Virol 2003 Sep; 71 (1): 115-23 (Pubitemid 37121921)
85. Polo C, Perez JL, Mielnichuck A, et al. Prevalence and patterns of polyomavirus urinary excretion in immunocompetent adults and children. Clin Microbiol Infect 2004 Jul; 10 (7): 640-4 (Pubitemid 39077052)
86. Clifford DB, De Luca A, Simpson DM, et al. Natalizumab-associated progressive multifocal leukoencephalopathy in patients with multiple sclerosis: lessons from 28 cases. Lancet Neurol 2010 Apr; 9 (4): 438-46
87. Borriello G, Prosperini L, Luchetti A, et al. Natalizumab treatment in pediatric multiple sclerosis: a case report. Eur J Paediatr Neurol 2009 Jan; 13 (1): 67-71
88. Huppke P, Stark W, Zurcher C, et al. Natalizumab use in pediatric multiple sclerosis. Arch Neurol 2008 Dec; 65 (12): 1655-8
89. Ghezzi A, Pozzilli C, Grimaldi LM, et al. Safety and efficacy of natalizumab in children with multiple sclerosis. Neurology 2010 Sep 7; 75 (10): 912-7
90. Weiner H, Ackin G, Orav E, et al. Intermittent cyclophosphamide pulse therapy in progressive multiple sclerosis: final report of the Northeast Cooperative Multiple Sclerosis Treatment Group. Neurology 1993; 43: 910-8 (Pubitemid 23150561)
91. Group TCcMS. The Canadian cooperative trial of cyclophosphamide and plasma exchange in progressive multiple sclerosis. Lancet 1991; 337: 441-6
92. Hartung H, Gonsette R, Konig N, et al. Mitoxantrone in progressive multiple sclerosis: a placebo-controlled, double-blind, randomized, multicenter trial. Lancet 2002; 360: 2018-25 (Pubitemid 36026580)
93. Ellis R, Boggild M. Therapy-related acute leukaemia with mitoxantrone: what is the risk and can we minimise it? Mult Scler 2009 Apr; 15 (4): 505-8
94. Pascual AM, Tellez N, Bosca I, et al. Revision of the risk of secondary leukaemia after mitoxantrone in multiple sclerosis populations is required. Mult Scler 2009 Nov; 15 (11): 1303-10
95. Kornek B, Bernert G, Rostasy K, et al. Long-term follow-up of pediatric patients treated with mitoxantrone for multiple sclerosis. Neuropediatrics 2011 Feb; 42 (1): 7-12
96. Lucchinetti C, Bruck W, Parisi J, et al. Heterogeneity of multiple sclerosis lesions: implications for the pathogenesis of demyelination. Ann Neurol 2000 Jun; 47 (6): 707-17 (Pubitemid 30390191)
97. Karenfort M, Kieseier BC, Tibussek D, et al. Rituximab as a highly effective treatment in a female adolescent with severe multiple sclerosis. Dev Med Child Neurol 2009 Feb; 51 (2): 159-61
98. Makhani N, Gorman MP, Branson HM, et al. Cyclophosphamide therapy in pediatric multiple sclerosis. Neurology 2009 Jun 16; 72 (24): 2076-82
99. Chun J, Hartung HP. Mechanism of action of oral fingolimod (FTY720) in multiple sclerosis. Clin Neuropharmacol 2010 Mar-Apr; 33 (2): 91-101
100. Kappos L, Gold R, Miller DH, et al. Efficacy and safety of oral fumarate in patients with relapsing-remitting multiple sclerosis: a multicentre, randomised, double-blind, placebo-controlled phase IIb study. Lancet 2008 Oct 25; 372 (9648): 1463-72
101. OConnor PW, Li D, Freedman MS, et al. A phase II study of the safety and efficacy of teriflunomide in multiple sclerosis with relapses. Neurology 2006 Mar 28; 66 (6): 894-900 (Pubitemid 43739766)
102. Comi G, Pulizzi A, Rovaris M, et al. Effect of laquinimod on MRI-monitored disease activity in patients with relapsing-remitting multiple sclerosis: a multicentre, randomised, double-blind, placebo-controlled phase IIb study. Lancet 2008 Jun 21; 371 (9630): 2085-92 (Pubitemid 351842581)
103. Delgado MR, Hirtz D, Aisen M, et al. Practice parameter: pharmacologic treatment of spasticity in children and adolescents with cerebral palsy (an evidence-based review): report of the Quality Standards Subcommittee of the American Academy of Neurology and the Practice Committee of the Child Neurology Society. Neurology Jan 26; 74 (4): 336-43
104. Feldman RG, Kelly-Hayes M, Conomy JP, et al. Baclofen for spasticity in multiple sclerosis: double-blind crossover and three-year study. Neurology 1978 Nov; 28 (11): 1094-8 (Pubitemid 9012848)
105. Bass B, Weinshenker B, Rice GP, et al. Tizanidine versus baclofen in the treatment of spasticity in patients with multiple sclerosis. Can J Neurol Sci 1988 Feb; 15 (1): 15-9 (Pubitemid 18067518)
106. Milla PJ, Jackson AD. A controlled trial of baclofen in children with cerebral palsy. J Int Med Res 1977; 5 (6): 398-404 (Pubitemid 8220590)
107. Lees AJ, Clarke CR, Harrison MJ. Hallucinations after withdrawal of baclofen [letter]. Lancet 1977 Apr 16; 1 (8016): 858
108. Hyser CL, Drake Jr ME. Status epilePticus after baclofen withdrawal. J Natl Med Assoc 1984 May; 76 (5): 533, 7-8
109. Chawla JM, Sagar R. Baclofen-induced psychosis. Ann Pharmacother. 2006 Nov; 40 (11): 2071-3 (Pubitemid 44747483)
110. DAleo G, Cammaroto S, Rifici C, et al. Hallucinations after abruPt withdrawal of oral and intrathecal baclofen. Funct Neurol 2007 Apr-Jun; 22 (2): 81-8 (Pubitemid 47249612)
111. Malhotra T, Rosenzweig I. Baclofen withdrawal causes psychosis in otherwise unclouded consciousness [letter]. J Neuropsychiatry Clin Neurosci 2009 Fall; 21 (4): 476
112. Hoving MA, van Raak EP, Spincemaille GH, et al. Efficacy of intrathecal baclofen therapy in children with intractable spastic cerebral palsy: a randomized controlled trial. Eur J Paediatr Neurol 2009 May; 13 (3): 240-6
113. Groves L, Shellenberger MK, Davis CS. Tizanidine treatment of spasticity: a meta-analysis of controlled, double-blind, comparative studies with baclofen and diazepam. Adv Ther 1998 Jul-Aug; 15 (4): 241-51 (Pubitemid 28454903)
114. Henney 3rd HR, Chez M. Pediatric safety of tizanidine: clinical adverse event database and retrospective chart assessment. Paediatr Drugs 2009; 11 (6): 397-406
115. Vasquez-Briceno A, Arellano-Saldana ME, Leon-Hernandez SR, et al. The usefulness of tizanidine: a one-year follow-up of the treatment of spasticity in infantile cerebral palsy. Rev Neurol 2006 Aug 1-15; 43 (3): 132-6 (Pubitemid 47574077)
116. Joynt RL, Leonard Jr JA. Dantrolene sodium suspension in treatment of spastic cerebral palsy. Dev Med Child Neurol 1980 Dec; 22 (6): 755-67 (Pubitemid 11243261)
117. Chan CH. Dantrolene sodium and hepatic injury. Neurology 1990 Sep; 40 (9): 1427-32 (Pubitemid 20291654)
118. Moore AP, Ade-Hall RA, Smith CT, et al. Two-year placebo-controlled trial of botulinum toxin A for leg spasticity in cerebral palsy. Neurology 2008 Jul 8; 71 (2): 122-8
119. Goldstein EM. Safety of high-dose botulinum toxin type A therapy for the treatment of pediatric spasticity. J Child Neurol 2006 Mar; 21 (3): 189-92 (Pubitemid 43891142)
120. Yeh E, Weinstock-Gutman B, Smerbeck A, et al. Fatigue and depression are seen more frequently in children with pediatric demyelinating disorders than healthy controls. ECTRIMS; 2011 Oct 19-22; Amsterdam
121. Morrato EH, Libby AM, Orton HD, et al. Frequency of provider contact after FDA advisory on risk of pediatric suicidality with SSRIs. Am J Psychiatry 2008 Jan; 165 (1): 42-50 (Pubitemid 351704551)
122. Gualano B, Sa Pinto AL, Perondi B, et al. Evidence for prescribing exercise as treatment in pediatric rheumatic diseases. Autoimmun Rev 2010 Jun; 9 (8): 569-73
123. Houghton KM, Tucker LB, Potts JE, et al. Fitness, fatigue, disease activity, and quality of life in pediatric lupus. Arthritis Rheum 2008 Apr 15; 59 (4): 537-45 (Pubitemid 351563537)
124. White PD, Goldsmith KA, Johnson AL, et al. Comparison of adaPtive pacing therapy, cognitive behaviour therapy, graded exercise therapy, and specialist medical care for chronic fatigue syndrome (PACE): a randomised trial. Lancet 2011 Mar 5; 377 (9768): 823-36
125. Gordon BA, Knapman LM, Lubitz L. Graduated exercise training and progressive resistance training in adolescents with chronic fatigue syndrome: a randomized controlled pilot study. Clin Rehabil 2010 Dec; 24 (12): 1072-9
126. Nunez M, Fernandez-Sola J, Nunez E, et al. Health-related quality of life in patients with chronic fatigue syndrome: group cognitive behavioural therapy and graded exercise versus usual treatment. A randomised controlled trial with 1 year of follow-up. Clin Rheumatol 2011 Mar; 30 (3): 381-9
127. McCullagh R, Fitzgerald AP, Murphy RP, et al. Long-term benefits of exercising on quality of life and fatigue in multiple sclerosis patients with mild disability: a pilot study. Clin Rehabil 2008 Mar; 22 (3): 206-14 (Pubitemid 351460989)
128. Petajan JH, Gappmaier E,White AT, et al. Impact of aerobic training on fitness and quality of life in multiple sclerosis. Ann Neurol 1996 Apr; 39 (4): 432-41 (Pubitemid 26117998)
129. Mostert S, Kesselring J. Effects of a short-term exercise training program on aerobic fitness, fatigue, health percePtion and activity level of subjects with multiple sclerosis. Mult Scler 2002 Apr; 8 (2): 161-8 (Pubitemid 34256754)
130. Oken BS, Kishiyama S, Zajdel D, et al. Randomized controlled trial of yoga and exercise in multiple sclerosis. Neurology 2004 Jun 8; 62 (11): 2058-64 (Pubitemid 38738221)
131. Cakt BD, Nacir B, Genc H, et al. Cycling progressive resistance training for people with multiple sclerosis: a randomized controlled study. Am J Phys Med Rehabil 2010 Jun; 89 (6): 446-57
132. Grossman P, Kappos L, Gensicke H, et al. MS quality of life, depression, and fatigue improve after mindfulness training: a randomized trial. Neurology 2010 Sep 28; 75 (13): 1141-9
133. ZifkoUA,RuppM, Schwarz S, et al.Modafinil in treatment of fatigue inmultiple sclerosis: results of an open-label study. J Neurol 2002 Aug; 249 (8): 983-7 (Pubitemid 35002216)
134. Rammohan KW, Lynn DJ. Modafinil for fatigue in MS: a randomized placebo- controlled double-blind study. Neurology 2005 Dec 27; 65 (12): 1995-7; author reply 1995-7
135. Rammohan KW, Rosenberg JH, Lynn DJ, et al. Efficacy and safety of modafinil (Provigil) for the treatment of fatigue in multiple sclerosis: a two centre phase 2 study. J Neurol Neurosurg Psychiatry 2002 Feb; 72 (2): 179-83
136. Stankoff B, Waubant E, Confavreux C, et al. Modafinil for fatigue in MS: a randomized placebo-controlled double-blind study. Neurology 2005 Apr 12; 64 (7): 1139-43
137. Biederman J, Swanson JM, Wigal SB, et al. Efficacy and safety of modafinil film-coated tablets in children and adolescents with attentiondeficit/ hyperactivity disorder: results of a randomized, double-blind, placebocontrolled, flexible-dose study. Pediatrics 2005 Dec; 116 (6): e777-84 (Pubitemid 46056456)
138. Kahbazi M, Ghoreishi A, Rahiminejad F, et al. A randomized, double-blind and placebo-controlled trial of modafinil in children and adolescents with attention deficit and hyperactivity disorder. Psychiatry Res 2009 Aug 15; 168(3): 234-7